ArticleAntimicrobial agents and chemotherapy2004
Activity of posaconazole combined with amphotericin B against Aspergillus flavus infection in mice: comparative studies in two laboratories.
Article in Antimicrobial agents and chemotherapy, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 51 citations in OpenAlex.
- Rodent Models of Invasive Aspergillosis due toFrontiers in microbiology · 2017Review
- Application of a low molecular weight antifungal protein from Penicillium chrysogenum (PAF) to treat pulmonary aspergillosis in mice.Emerging microbes & infections · 2016Article
- In Vivo Synergy of Amphotericin B plus Posaconazole in Murine Aspergillosis.Antimicrobial agents and chemotherapy · 2016Article
- Evaluation of Antifungal Activity and Mode of Action of New Coumarin Derivative, 7-Hydroxy-6-nitro-2H-1-benzopyran-2-one, against Aspergillus spp.Evidence-based complementary and alternative medicine : eCAM · 2015Article
- Susceptibility breakpoints for amphotericin B and Aspergillus species in an in vitro pharmacokinetic-pharmacodynamic model simulating free-drug concentrations in human serum.Antimicrobial agents and chemotherapy · 2014Article
- Pharmacokinetic/pharmacodynamic profile of posaconazole.Clinical pharmacokinetics · 2010Review
- Article
- Posaconazole enhances the activity of amphotericin B against Aspergillus hyphae in vitro.Antimicrobial agents and chemotherapy · 2007Article
- Standardization of an experimental murine model of invasive pulmonary aspergillosis.Antimicrobial agents and chemotherapy · 2006Article
- In vivo efficacy of aerosolized nanostructured itraconazole formulations for prevention of invasive pulmonary aspergillosis.Antimicrobial agents and chemotherapy · 2006Article
- Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis.Antimicrobial agents and chemotherapy · 2006Article
- Interaction between posaconazole and amphotericin B in concomitant treatment against Candida albicans in vivo.Antimicrobial agents and chemotherapy · 2005Article
- Posaconazole.Drugs · 2005Review
- Combination treatment of invasive fungal infections.Clinical microbiology reviews · 2005Review
- Efficacy of posaconazole in a murine model of central nervous system aspergillosis.Antimicrobial agents and chemotherapy · 2004Article
- Posaconazole and amphotericin B combination therapy against Cryptococcus neoformans infection.Antimicrobial agents and chemotherapy · 2004Article
- Challenges in designing animal studies to detect antagonism of polyene activity.Antimicrobial agents and chemotherapy · 2004Article
- A new coumarin derivative, 4-acetatecoumarin, with antifungal activity and association study against Aspergillus spp.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]Article
Corrections and comments
- Commented on by
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Posaconazole and/or amphotericin B was given to mice pretreated with a steroid and then infected by inhalation of Aspergillus flavus conidia. Two laboratories conducted studies using almost identical protocols to evaluate both survival and lung tissue burdens 8 days after infection. The results of the in vivo studies performed at both laboratories were consistent. We found that (i). up to 5 mg of amphotericin B per kg of body weight was poorly effective in treating invasive aspergillosis; (ii). posaconazole at 2 or 10 mg/kg/dose prolonged survival and reduced lung tissue CFU; and (iii). there was generally no antagonistic interaction of the drugs in combination, even when the experiments were designed to maximize the likelihood of antagonism. These studies do not confirm the antagonistic interaction of triazoles and polyenes reported by others.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.